•
Sep 30, 2022
CervoMed Q3 2022 Earnings Report
Provided an update on the strategic opportunities and its 2022 annual meeting of stockholders.
Key Takeaways
Diffusion Pharmaceuticals is actively pursuing a strategy to deliver stockholder value, including a possible sale, merger, or recapitalization. The company is in active bidding stage but the Board rejected an unsolicited offer from a LifeSci Capital client as inadequate, leading to a proxy contest.
Diffusion is evaluating strategic opportunities to enhance stockholder value.
The company is in the active bidding stage and encouraged by the response to the Strategic Review Process.
The Board rejected an unsolicited offer from a LifeSci Capital client.
LifeSci commenced a proxy contest for control of the Diffusion Board.